
Cohorts and Genomics
Establish precision monitoring tools to guide societal restrictions and future vaccination strategies, identify risk factors for SARS-CoV-2 infection and complications in Diabetes and Chronic Lung Disease patients. We are using KORA, NAKO cohorts and available biobanks from diabetes and chronic lung disease patient cohorts.

Therapeutics
Identify biomolecules and antibodies with antiviral and neutralizing functions in preclinical settings to enter clinical development as soon as possible. Predict viral targets for therapeutic intervention using AI powered tools. Time frame for the delivery of first results is estimated around six months.

Data-based approaches
Large-scale analysis of airway single-cell atlases to identify cell-type specific vulnerabilities

Collaborations
Interaction and synergies with other institutions is key. We work closely with TUM and LMU, the German Centers for Health Research and of course we work closely with the Helmholtz Association and Helmholtz Health Research.